drugset / Trial / NCT01533506

Stiripentol in Dravet Syndrome

NCT01533506

Expanded access No longer available Mayo Clinic

Summary

The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

Timeline

Start
2012-02
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Stiripentol Small molecule 30 mg/kg

Indications